Guidance for the 2025/26 financial year

ANNOUNCEMENT NO. 291

11 September 2025

Guidance for the 2025/26 financial year 

ChemoMetec today approved the annual report for 2024/25, including the guidance for 2025/26, which is considered inside information.

For 2025/26, ChemoMetec expects revenue in the range of DKK 545-565 million (2024/25: DKK 495.6 million) and EBITDA in the range of DKK 295-315 million (2024/25: DKK 258.0 million).

The annual report for 2024/25, which is released along with this announcement, sets out the underlying assumptions applied in the preparation of the guidance for 2025/26 (p. 39-40).

Additional information

Martin Helbo Behrens, CEO
Tel.: (+45) 48 13 10 20

Kim Nicolajsen, CFO
Tel.: (+45) 48 13 10 20

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.

You May Also Be Interested In

• Enovix’s TAA-Compliant Battery Manufacturing Strengthens Position with U.S. Defense Supply Chain
• STRYK(TM) Brands Appoints Marchant Kuys as President and Chief Executive Officer
• Try Before You Buy: Azazie Brings In-Person Bridesmaid Dress Experience to San Diego